Akebia Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.65
Dividend & YieldN/A$ (N/A)
Beta 1.33
Market capitalization 45.99M
Operating cash flow -81.28M
ESG Scores unknown

Company description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -53.22M -38.37M -28.71M -9.91M
Total Cashflows From Investing Activities 36.59M 211.18M -40M 39.94M
Net Borrowings -19k 62.67M 19.98M
Total Cash From Financing Activities 96.56M 88.97M 231.72M 133.73M
Change To Operating Activities 55.83M -9.36M -3.13M -48.63M
Issuance Of Stock 96.58M 26.73M 211.75M 88.95M
Net Income -143.59M -279.66M -383.46M -282.84M
Change In Cash 35.66M 42.7M 81.33M -79.29M
Effect Of Exchange Rate
Total Cash From Operating Activities -97.49M -257.44M -110.39M -252.97M
Depreciation 2.42M 38.65M 33.59M 37.97M
Change To Account Receivables 33.38M -22.2M 12.01M -24.02M
Other Cashflows From Financing Activities 44.78M 44.78M 44.78M 44.78M
Change To Netincome 7.66M 82.64M 253.15M 100.32M
Capital Expenditures -1.61M -6.66M -317k -59k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -171.93M -286.29M -383.46M -282.84M
Net Income -143.59M -279.66M -383.46M -282.84M
Selling General Administrative 87.06M 149.46M 153.95M 174.16M
Gross Profit -84.81M -93.32M 12.86M -17.92M
Ebit -173.39M -279.18M -172.6M -228.12M
Operating Income -173.39M -279.18M -172.6M -228.12M
Interest Expense -27k -27k -8.92M -20.02M
Income Tax Expense -28.34M -6.63M
Total Revenue 207.74M 335M 295.31M 213.58M
Cost Of Revenue 292.55M 428.32M 282.45M 231.5M
Total Other Income ExpenseNet 1.46M -7.11M -210.85M -54.72M
Net Income From Continuing Ops -143.59M -279.66M -383.46M -282.84M
Net Income Applicable To Common Shares -143.59M -279.66M -383.46M -282.84M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 360.61M 376.44M 396.52M 449.09M
Total Stockholder Equity 635.93M 394.76M 247.62M 76.46M
Other Current Liabilities 73.05M 39.83M 15.21M 20.91M
Total Assets 996.54M 771.2M 644.14M 525.55M
Common Stock 1k 1k 1k 1k
Other Current Assets 263k 395k 2M
Retained Earnings -514.39M -794.05M -1.18B -1.46B
Treasury Stock -261k 13k 6k
Cash 104.64M 147.45M 228.7M 149.8M
Total Current Liabilities 265.69M 208.12M 187.15M 256.49M
Other Stockholder Equity -261k 13k 6k
Property, Plant, and Equipment 8.02M 39.42M 35.5M 40.61M
Total Current Assets 468.27M 309.53M 371.44M 272.01M
Net Tangible Assets 252.72M 48.49M 48.4M -86.72M
Net Receivables 16.67M 38.86M 28.57M 55.18M
Accounts Payable 42.8M 39.22M 41.31M 33.59M


Insider Transactions

Here are the insider transactions of stock shares related to Akebia Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BURKE STEVEN KEITHSale at price 0.36 per share.D2022-08-31Officer1.15k
ZUMWALT LEANNE MStock Award(Grant) at price 0.00 per share.D2022-06-08Director13.7k
ROGERS MICHAEL WStock Award(Grant) at price 0.00 per share.D2022-06-08Director13.7k
ADAMS ADRIANStock Award(Grant) at price 0.00 per share.D2022-06-08Director13.7k
GILMAN STEVEN CStock Award(Grant) at price 0.00 per share.D2022-06-08Director13.7k
SPELLMAN DAVID A.Stock Award(Grant) at price 0.00 per share.D2022-06-08Chief Financial Officer200k
SMITH CYNTHIAStock Award(Grant) at price 0.00 per share.D2022-06-08Director13.7k
WOLF MYLESStock Award(Grant) at price 0.00 per share.D2022-06-08Director13.7k
FRIESON RONStock Award(Grant) at price 0.00 per share.D2022-06-08Director13.7k
GILMAN STEVEN CSale at price 0.36 per share.D2022-06-03Director4.57k
BURKE STEVEN KEITHStock Award(Grant) at price 0.00 per share.D2022-05-12Officer200k
COTREAU VIOLETTAStock Award(Grant) at price 0.00 per share.D2022-05-12Officer150k
BURKE STEVEN KEITHSale at price 2.15 - 2.17 per share.D2022-03-01Officer15.06k
BUTLER JOHN PSale at price 2.15 - 2.17 per share.D2022-03-01Chief Executive Officer79.03k
HADAS NICOLE RSale at price 2.15 - 2.17 per share.D2022-03-01Officer21.06k
DAHAN MICHELSale at price 2.15 - 2.17 per share.D2022-03-01Chief Operating Officer21.53k
SPELLMAN DAVID A.Sale at price 2.15 - 2.17 per share.D2022-03-01Chief Financial Officer8.2k
FAULKINGHAM DELL JSale at price 2.15 - 2.17 per share.D2022-03-01Officer13.18k
BURKE STEVEN KEITHStock Award(Grant) at price 0.00 per share.D2022-02-28Officer60k
BUTLER JOHN PStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Executive Officer293.12k
HADAS NICOLE RStock Award(Grant) at price 0.00 per share.D2022-02-28Officer50k
DAHAN MICHELStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Operating Officer50k
SPELLMAN DAVID A.Stock Award(Grant) at price 0.00 per share.D2022-02-28Chief Financial Officer60k
FAULKINGHAM DELL JStock Award(Grant) at price 0.00 per share.D2022-02-28Officer50k
COTREAU VIOLETTAStock Award(Grant) at price 0.00 per share.D2022-02-28Officer40.83k
COTREAU VIOLETTASale at price 2.15 per share.D2022-02-28Officer3.95k
COTREAU VIOLETTASale at price 2.29 per share.D2022-01-03Officer5.83k
BURKE STEVEN KEITHSale at price 2.83 per share.D2021-08-31Officer1.04k
GILMAN STEVEN CSale at price 3.32 per share.D2021-06-07Director4.57k
HEFFERNAN MICHAEL THOMASStock Award(Grant) at price 0.00 per share.D2021-06-02Director13.7k
ROGERS MICHAEL WStock Award(Grant) at price 0.00 per share.D2021-06-02Director13.7k
ADAMS ADRIANStock Award(Grant) at price 0.00 per share.D2021-06-02Director13.7k
GILMAN STEVEN CStock Award(Grant) at price 0.00 per share.D2021-06-02Director13.7k
SMITH CYNTHIAStock Award(Grant) at price 0.00 per share.D2021-06-02Director13.7k
WOLF MYLESStock Award(Grant) at price 0.00 per share.D2021-06-02Director13.7k
BURKE STEVEN KEITHSale at price 3.40 per share.D2021-04-01Officer1.08k
BUTLER JOHN PSale at price 3.40 per share.D2021-04-01Chief Executive Officer4.11k
HADAS NICOLE RSale at price 3.40 per share.D2021-04-01Officer1.06k
DAHAN MICHELSale at price 3.40 per share.D2021-04-01Chief Operating Officer1.21k
SPELLMAN DAVID A.Sale at price 3.40 per share.D2021-04-01Chief Financial Officer790
FAULKINGHAM DELL JSale at price 3.40 per share.D2021-04-01Officer952
BURKE STEVEN KEITHStock Award(Grant) at price 0.00 per share.D2021-03-16Officer10.4k
BUTLER JOHN PStock Award(Grant) at price 0.00 per share.D2021-03-16Chief Executive Officer39.52k
HADAS NICOLE RStock Award(Grant) at price 0.00 per share.D2021-03-16Officer10.19k
DAHAN MICHELStock Award(Grant) at price 0.00 per share.D2021-03-16Chief Operating Officer11.65k
SPELLMAN DAVID A.Stock Award(Grant) at price 0.00 per share.D2021-03-16Chief Financial Officer7.59k
FAULKINGHAM DELL JStock Award(Grant) at price 0.00 per share.D2021-03-16Officer9.15k
BURKE STEVEN KEITHSale at price 3.40 per share.D2021-03-01Officer7.56k
BUTLER JOHN PSale at price 3.40 per share.D2021-03-01Chief Executive Officer49.99k
HADAS NICOLE RSale at price 3.40 per share.D2021-03-01Officer14.29k
DAHAN MICHELSale at price 3.40 per share.D2021-03-01Chief Operating Officer14.55k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Akebia Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Akebia Therapeutics Inc

Here is the result of two systematic investment strategies applied to Akebia Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Akebia Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Akebia Therapeutics Inc:

Akebia Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -39.12% on the backtest period.

Performance at glance

Performance

-39.12 %

Latent gain

-681.53 $

Invested capital

1742.19 $

Annualized return

-9.54 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Akebia Therapeutics Inc

This is the result of two momentum investment strategies applied to Akebia Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Akebia Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Akebia Therapeutics Inc:

Akebia Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -28.62% of return on Akebia Therapeutics Inc. That represents -1355.42$ of latent gain with 4736.64$ of employed capital.
  • The second momentum investment strategy would give -38.36% of return on Akebia Therapeutics Inc. That represents -1819.55$ of latent gain with 4743.69$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-28.62 %

Latent gain

-1355.42 $

Invested capital

4736.64 $

Annualized return

-28.67 %
Performance at glance (2Q Momentum)

Performance

-38.36 %

Latent gain

-1819.55 $

Invested capital

4743.69 $

Annualized return

-10.6 %

Momentum equity curve on Akebia Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Akebia Therapeutics Inc:

Akebia Therapeutics Inc momentum equity

Note: the dividends potentially given by Akebia Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Akebia Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Akebia Therapeutics Inc since the beginning:

Akebia Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Akebia Therapeutics Inc

Buy the dip entry openings on Akebia Therapeutics Inc

Akebia Therapeutics Inc

The performance achieved by the robo-advisor on Akebia Therapeutics Inc is -60.2%. That represents -301.35$ of latent gain with 500.59$ of employed capital. The following chart shows Akebia Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Akebia Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-60.2 %

Latent gain

-301.35 $

Invested capital

500.59 $

Annualized return

-28.67 %

Equity curve of the strategy applied to Akebia Therapeutics Inc

The following chart shows the result of the investment strategy applied to Akebia Therapeutics Inc:

Akebia Therapeutics Inc

Note: the dividends potentially given by Akebia Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Akebia Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Akebia Therapeutics Inc:

Akebia Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Akebia Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Akebia Therapeutics Inc.

Equity curve comparison on Akebia Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Akebia Therapeutics Inc investment strategy comparison

Employed capital comparison on Akebia Therapeutics Inc

Akebia Therapeutics Inc investment comparison

Performance comparison on Akebia Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -39.12% -681.53$ 1742.19$ -9.54%
Momentum 1 quarter -28.62% -1355.42$ 4736.64$ -7.41%
Momentum 2 quarters -38.36% -1819.55$ 4743.69$ -10.6%
Non-directional -60.2% -301.35$ 500.59$ -28.67%
Annualized return comparison

Automatic investment

-9.54 %

Momentum 1Q

-10.6 %

Momentum 2Q

-10.6 %

Non-directional

-28.67 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Akebia Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Akebia Therapeutics Inc

  • Most correlated stocks last 3 months

  • BANKOFJIUJIANG
  • Akebia Therapeutics Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • BONNY HLDG

  • Note: The algorithm computes the probability of correlation between Akebia Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Akebia Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Akebia Therapeutics Inc
    Country United States
    City Cambridge
    Address 245 First Street
    Phone 617 871 2098
    Website www.akebia.com
    FullTime employees 426
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker AKBA
    Market www.nasdaq.com

    Akebia Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown